1887

Abstract

Increased recognition of parvovirus B19 (B19), an erythrovirus, as a significant human pathogen that causes fetal loss and severe disease in immunocompromised patients has resulted in intensive efforts to understand the pathogenesis of B19-related disease, to improve diagnostic strategy that is deployed to detect B19 infection and blood-product contamination and, finally, to elucidate the nature of the cellular immune response that is elicited by the virus in diverse patient cohorts. It is becoming clear that at least three related erythrovirus strains (B19, A6/K71 and V9) are circulating in the general population and that viral entry into target cells is mediated by an expanding range of cellular receptors, including P antigen and β-integrins. Persistent infection by B19 is emerging as a contributory factor in autoimmune disease, a hypothesis that is constrained by the detection of B19 in the skin of apparently healthy individuals. B19 infection during pregnancy may account for thousands of incidences of fetal loss per annum in Europe, North America and beyond, yet there is currently only minimal screening of pregnant women to assess serological status, and thereby risk of infection, upon becoming pregnant. Whilst major advances in diagnosis of B19 infection have taken place, including standardization of serological and DNA-based detection methodologies, blood donations that are targeted at high-risk groups are only beginning to be screened for B19 IgG and DNA as a means of minimizing exposure of at-risk patients to the virus. It is now firmly established that a Th1-mediated cellular immune response is mounted in immunocompetent individuals, a finding that should contribute to the development of an effective vaccine to prevent B19 infection in selected high-risk groups, including sickle-cell anaemics.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05485-0
2004-06-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/6/JM530601.html?itemId=/content/journal/jmm/10.1099/jmm.0.05485-0&mimeType=html&fmt=ahah

References

  1. Aberham, C., Pendl, C., Gross, P., Zerlauth, G. & Gessner, M. ( 2001;). A quantitative, internally controlled real-time PCR assay for the detection of parvovirus B19 DNA. J Virol Methods 92, 183–191.[CrossRef]
    [Google Scholar]
  2. Alger, L. S. ( 1997;). Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am 11, 55–75.[CrossRef]
    [Google Scholar]
  3. Anderson, M. J., Jones, S. E., Fisher-Hoch, S. P., Lewis, E., Hall, S. M., Bartlett, C. L. R., Cohen, B. J., Mortimer, P. P. & Pereira, M. S. ( 1983;). Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet i, 1378.
  4. Anderson, L. J., Gillespie, S. M., Torok, T. J., Hurwitz, E. S., Tsou, C. J. & Gary, G. W. ( 1990;). Risk of infection following exposures to human parvovirus B19. Behring Inst Mitt 85, 60–63.
    [Google Scholar]
  5. Anderson, M. J., Higgins, P. G., Davis, L. R., Willman, J. S., Jones, S. E., Kidd, I. M., Pattison, J. R. & Tyrrell, D. A. J. ( 1985;). Experimental parvoviral infection in humans. J Infect Dis 152, 257–265.[CrossRef]
    [Google Scholar]
  6. Ballou, W. R., Reed, J. L., Noble, W., Young, N. S. & Koenig, S. ( 2003;). Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 187, 675–678.[CrossRef]
    [Google Scholar]
  7. Barton, L. L., Lax, D., Shehab, Z. M. & Keith, J. C. ( 1997;). Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 133, 131–133.[CrossRef]
    [Google Scholar]
  8. Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J. F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. & Klein, B. ( 1995;). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685–691.
    [Google Scholar]
  9. Beland, S. S., Daniel, G. K., Menard, J. C. & Miller, N. M. ( 1997;). Aplastic crisis associated with parvovirus B19 in an adult with hereditary spherocytosis. J Ark Med Soc 94, 163–164.
    [Google Scholar]
  10. Berry, P. J., Gray, E. S., Porter, H. J. & Burton, P. A. ( 1992;). Parvovirus infection of the human fetus and newborn. Semin Diagn Pathol 9, 4–12.
    [Google Scholar]
  11. Blümel, J., Schmidt, I., Willkommen, H. & Löwer, J. ( 2002;). Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 42, 1011–1018.[CrossRef]
    [Google Scholar]
  12. Blundell, M. C., Beard, C. & Astell, C. R. ( 1987;). In vitro identification of a B19 parvovirus promoter. Virology 157, 534–538.[CrossRef]
    [Google Scholar]
  13. Bousquet, F., Segondy, M., Faure, J.-M., Deschamps, F. & Boulot, P. ( 2000;). B19 parvovirus-induced fetal hydrops: good outcome after intrauterine blood transfusion at 18 weeks of gestation. Fetal Diagn Ther 15, 132–133.[CrossRef]
    [Google Scholar]
  14. Brown, K. E. & Young, N. S. ( 1997;). Human parvovirus B19 infections in infants and children. Adv Pediatr Infect Dis 13, 101–126.
    [Google Scholar]
  15. Brown, T., Anand, A., Ritchie, L. D., Clewley, J. P. & Reid, T. M. ( 1984;). Intrauterine parvovirus infection associated with hydrops fetalis. Lancet ii, 1033–1034.
  16. Brown, C. S., Salimans, M. M. M., Noteborn, M. H. M. & Weiland, H. T. ( 1990;). Antigenic parvovirus B19 coat proteins VP1 and VP2 produced in large quantities in a baculovirus expression system. Virus Res 15, 197–211.[CrossRef]
    [Google Scholar]
  17. Brown, K. E., Anderson, S. M. & Young, N. S. ( 1993;). Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262, 114–117.[CrossRef]
    [Google Scholar]
  18. Brown, K. E., Hibbs, J. R., Gallinella, G., Anderson, S. M., Lehman, E. D., McCarthy, P. & Young, N. S. ( 1994;). Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330, 1192–1196.[CrossRef]
    [Google Scholar]
  19. Cameron, A. D., Swain, S. & Patrick, W. J. ( 1997;). Human parvovirus B19 infection associated with hydrops fetalis. Aust N Z J Obstet Gynaecol 37, 316–319.[CrossRef]
    [Google Scholar]
  20. Cassinotti, P. & Siegl, G. ( 2000;). Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 19, 886–887.[CrossRef]
    [Google Scholar]
  21. Cassinotti, P., Weitz, M. & Siegl, G. ( 1993;). Human parvovirus B19 infections: routine diagnosis by a new nested polymerase chain reaction assay. J Med Virol 40, 228–234.[CrossRef]
    [Google Scholar]
  22. Cassinotti, P., Bas, S., Siegl, G. & Vischer, T. L. ( 1995;). Association between human parvovirus B19 infection and arthritis. Ann Rheum Dis 54, 498–500.[CrossRef]
    [Google Scholar]
  23. Chen, M.-Y., Hung, C.-C., Fang, C.-T. & Hsieh, S.-M. ( 2001;). Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 32, 1361–1365.[CrossRef]
    [Google Scholar]
  24. Chia, J. K. & Jackson, B. ( 1996;). Myopericarditis due to parvovirus B19 in an adult. Clin Infect Dis 23, 200–201.[CrossRef]
    [Google Scholar]
  25. Chipman, P. R., Agbandje-McKenna, M., Kajigaya, S., Brown, K. E., Young, N. S., Baker, T. S. & Rossmann, M. G. ( 1996;). Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci USA 93, 7502–7506.[CrossRef]
    [Google Scholar]
  26. Clewley, J. P. ( 1984;). Biochemical characterization of a human parvovirus. J Gen Virol 65, 241–245.[CrossRef]
    [Google Scholar]
  27. Clewley, J. P., Cohen, B. J. & Field, A. M. ( 1987;). Detection of parvovirus B19 DNA, antigen, and particles in the human fetus. J Med Virol 23, 367–376.[CrossRef]
    [Google Scholar]
  28. Cohen, B. J. & Bates, C. M. ( 1995;). Evaluation of 4 commercial test kits for parvovirus B19-specific IgM. J Virol Methods 55, 11–25.[CrossRef]
    [Google Scholar]
  29. Cooling, L. L., Koerner, T. A. & Naides, S. J. ( 1995;). Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 172, 1198–1205.[CrossRef]
    [Google Scholar]
  30. Corcoran, A., Doyle, S., Waldron, D., Nicholson, A. & Mahon, B. P. ( 2000;). Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 74, 9903–9910.[CrossRef]
    [Google Scholar]
  31. Corcoran, A., Mahon, B. P., McParland, P., Davoren, A. & Doyle, S. ( 2003;). Ex vivo cytokine responses against parvovirus B19 antigens in previously infected pregnant women. J Med Virol 70, 475–480.[CrossRef]
    [Google Scholar]
  32. Corcoran, A., Mahon, B. P. & Doyle, S. ( 2004;). B cell memory is directed towards conformational epitopes of parvovirus B19 capsid proteins and the VP1-unique region. J Infect Dis (in press).
  33. Cossart, Y. E., Field, A. M., Cant, B. & Widdows, D. ( 1975;). Parvovirus-like particles in human sera. Lancet i, 72–73.
  34. Cotmore, S. F. & Tattersall, P. ( 1984;). Characterization and molecular cloning of a human parvovirus genome. Science 226, 1161–1165.[CrossRef]
    [Google Scholar]
  35. Coulombel, L., Morinet, F., Mielot, F. & Tchernia, G. ( 1989;). Parvovirus infection, leukaemia, and immunodeficiency. Lancet i, 101–102.
  36. Crowley, B., Kokai, G. & Cohen, B. ( 2001;). Human parvovirus B19 and fetal death. Lancet 358, 1180–1181.[CrossRef]
    [Google Scholar]
  37. Daly, P., Corcoran, A., Mahon, B. P. & Doyle, S. ( 2002;). High-sensitivity PCR detection of parvovirus B19 in plasma. J Clin Microbiol 40, 1958–1962.[CrossRef]
    [Google Scholar]
  38. Davenport, R., Geohas, G., Cohen, S., Beach, K., Lazo, A., Lucchesi, K. & Pehta, J. ( 2000;). Phase IV study of Plas+®SD: hepatitis A (HAV) and parvovirus B19 (B19) safety results. Blood 96, 1942. 1942.
    [Google Scholar]
  39. Dieck, D., Schild, R. L., Hansmann, M. & Eis-Hübinger, A. M. ( 1999;). Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn 19, 1119–1123.[CrossRef]
    [Google Scholar]
  40. Doyle, S., Kerr, S., O'Keeffe, G., O'Carroll, D., Daly, P. & Kilty, C. ( 2000;). Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. J Virol Methods 90, 143–152.[CrossRef]
    [Google Scholar]
  41. Eis-Hübinger, A. M., Oldenburg, J., Brackmann, H. H., Matz, B. & Schneweis, K. E. ( 1996;). The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentbl Bakteriol 284, 232–240.[CrossRef]
    [Google Scholar]
  42. Enders, G. & Biber, M. ( 1990;). Parvovirus B19 infections in pregnancy. Behring Inst Mitt 85, 74–78.
    [Google Scholar]
  43. Ennis, O., Corcoran, A., Kavanagh, K., Mahon, B. P. & Doyle, S. ( 2001;). Baculovirus expression of parvovirus B19 (B19V) NS1: utility in confirming recent infection. J Clin Virol 22, 55–60.[CrossRef]
    [Google Scholar]
  44. Erdman, D. D., Usher, M. J., Tsou, C., Caul, E. O., Gary, G. W., Kajigaya, S., Young, N. S. & Anderson, L. J. ( 1991;). Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 35, 110–115.[CrossRef]
    [Google Scholar]
  45. Erdman, D. D., Anderson, B. C., Török, T. J., Finkel, T. H. & Anderson, L. J. ( 1997;). Possible transmission of parvovirus B19 from intravenous immune globulin. J Med Virol 53, 233–236.[CrossRef]
    [Google Scholar]
  46. Eurostat ( 1998;). Statistics in Focus: Population and Social Conditions (ISSN 1024-4352, cat. no. CA-NK-98-001-EN-C). Luxembourg: European Commission.
  47. Fairley, C. K., Smoleniec, J. S., Caul, O. E. & Miller, E. ( 1995;). Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 346, 1335–1337.[CrossRef]
    [Google Scholar]
  48. Ferguson, M., Walker, D. & Cohen, B. ( 1997;). Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. Biologicals 25, 283–288.[CrossRef]
    [Google Scholar]
  49. Foto, F., Saag, K. G., Scharosch, L. L., Howard, E. J. & Naides, S. J. ( 1993;). Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J Infect Dis 167, 744–748.[CrossRef]
    [Google Scholar]
  50. Franssila, R., Hokynar, K. & Hedman, K. ( 2001;). T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus B19. J Infect Dis 183, 805–809.[CrossRef]
    [Google Scholar]
  51. Frickhofen, N., Abkowitz, J. L., Safford, M. & 10 other authors ( 1990;). Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 113, 926–933.[CrossRef]
    [Google Scholar]
  52. Gallinella, G., Manaresi, E., Zuffi, E., Venturoli, S., Bonsi, L., Bagnara, G. P., Musiani, M. & Zerbini, M. ( 2000;). Different patterns of restriction to B19 parvovirus replication in human blast cell lines. Virology 278, 361–367.[CrossRef]
    [Google Scholar]
  53. Graeve, J. L., de Alarcon, P. A. & Naides, S. J. ( 1989;). Parvovirus B19 infection in patients receiving cancer chemotherapy: the expanding spectrum of disease. Am J Pediatr Hematol Oncol 11, 441–444.
    [Google Scholar]
  54. Gray, A., Guillou, L., Zufferey, J., Rey, F., Kurt, A.-M., Jichlinski, P., Leisinger, H.-J. & Benhattar, J. ( 1998;). Persistence of parvovirus B19 DNA in testis of patients with testicular germ cell tumours. J Gen Virol 79, 573–579.
    [Google Scholar]
  55. Grilli, E. A., Anderson, A. J. & Hoskins, T. W. ( 1989;). Concurrent outbreaks of influenza and parvovirus B19 in a boys’ boarding school. Epidemiol Infect 103, 359–369.[CrossRef]
    [Google Scholar]
  56. Groeneveld, K. & van der Noordaa, J. ( 2003;). Blood products and parvovirus B19. Neth J Med 61, 154–156.
    [Google Scholar]
  57. Hall, S. M., Cohen, B. J., Mortimer, P. P., Caul, E. O., Cradock-Watson, J., Anderson, M. J., Pattison, J. R., Shriley, J. A. & Peto, T. E. A. ( 1990;). Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 300, 1166–1170.[CrossRef]
    [Google Scholar]
  58. Hansmann, M., Gembruch, U. & Bald, R. ( 1989;). New therapeutic aspects in nonimmune hydrops fetalis based on four hundred and two prenatally diagnosed cases. Fetal Ther 4, 29–36.[CrossRef]
    [Google Scholar]
  59. Hart, H. F., Hart, W. G., Crossley, J., Perrie, A. M., Wood, D. J., John, A. & McOmish, F. ( 1994;). Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang 67, 345–350.[CrossRef]
    [Google Scholar]
  60. Health Council for the Netherlands ( 2002;). Blood Products and Parvovirus B19: ‘Alerting’ Advisory Report (publication no. 2002/07; ISBN 90-5549-432-1). The Hague: Health Council for the Netherlands.
  61. Hedrick, J. ( 1996;). The effects of human parvovirus B19 and cytomegalovirus during pregnancy. J Perinat Neonatal Nurs 10, 30–39.[CrossRef]
    [Google Scholar]
  62. Heegaard, E. D. & Hornsleth, A. ( 1995;). Parvovirus: the expanding spectrum of disease. Acta Paediatr 84, 109–117.[CrossRef]
    [Google Scholar]
  63. Heegaard, E. D., Panum Jensen, I. & Christensen, J. ( 2001;). Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. J Med Virol 65, 362–367.[CrossRef]
    [Google Scholar]
  64. Heegaard, E. D., Rasksen, C. J. & Christensen, J. ( 2002a;). Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen. J Med Virol 67, 375–383.[CrossRef]
    [Google Scholar]
  65. Heegaard, E. D., Petersen, B. L., Heilmann, C. J. & Hornsleth, A. ( 2002b;). Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 40, 933–936.[CrossRef]
    [Google Scholar]
  66. Hemauer, A., Gigler, A., Searle, K., Beckenlehner, K., Raab, U., Broliden, K., Wolf, H., Enders, G. & Modrow, S. ( 2000;). Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women. J Med Virol 60, 48–55.[CrossRef]
    [Google Scholar]
  67. Hokynar, K., Söderlund-Venermo, M., Pesonen, M., Ranki, A., Kiviluoto, O., Partio, E. K. & Hedman, K. ( 2002;). A new parvovirus genotype persistent in human skin. Virology 302, 224–248.[CrossRef]
    [Google Scholar]
  68. Jawad, A. S. M. ( 1993;). Persistent arthritis after human parvovirus infection. Lancet 341, 494. 494.
    [Google Scholar]
  69. Jindal, H. K., Yong, C. B., Wilson, G. M., Tam, P. & Astell, C. R. ( 1994;). Mutations in the NTP-binding motif of minute virus of mice (MVM) NS-1 protein uncouple ATPase and DNA helicase functions. J Biol Chem 269, 3283–3289.
    [Google Scholar]
  70. Jones, L. P., Erdman, D. D. & Anderson, L. J. ( 1999;). Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 180, 500–504.[CrossRef]
    [Google Scholar]
  71. Jordan, J. A. ( 1996;). Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 174, 37–42.[CrossRef]
    [Google Scholar]
  72. Jordan, J. A. ( 2000;). Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J Clin Microbiol 38, 1472–1475.
    [Google Scholar]
  73. Jordan, J. A. & DeLoia, J. A. ( 1999;). Globoside expression within the human placenta. Placenta 20, 103–108.[CrossRef]
    [Google Scholar]
  74. Jordan, J. A., Huff, D. & DeLoia, J. A. ( 2001;). Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 8, 288–292.
    [Google Scholar]
  75. Kaikkonen, L., Lankinen, H., Harjunpää, I., Hokynar, K., Söderlund-Venermo, M., Oker-Blom, C., Hedman, L. & Hedman, K. ( 1999;). Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J Clin Microbiol 37, 3952–3956.
    [Google Scholar]
  76. Kajigaya, S., Shimada, T., Fujita, S. & Young, N. S. ( 1989;). A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci USA 86, 7601–7605.[CrossRef]
    [Google Scholar]
  77. Kajigaya, S., Fujii, H., Field, A., Anderson, S., Rosenfeld, S., Anderson, L. J., Shimada, T. & Young, N. S. ( 1991;). Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 88, 4646–4650.[CrossRef]
    [Google Scholar]
  78. Kerr, J. R., Curran, M. D., Moore, J. E., Coyle, P. V. & Ferguson, W. P. ( 1995a;). Persistent parvovirus B19 infection. Lancet 345, 1118. 1118.
    [Google Scholar]
  79. Kerr, J. R., O'Neill, H. J., Deleys, R., Wright, C. & Coyle, P. V. ( 1995b;). Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins. J Immunol Methods 180, 101–106.[CrossRef]
    [Google Scholar]
  80. Kerr, S., O'Keeffe, G., Kilty, C. & Doyle, S. ( 1999;). Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 57, 179–185.[CrossRef]
    [Google Scholar]
  81. Kerr, J. R., Barah, F., Mattey, D. L., Laing, I., Hopkins, S. J., Hutchinson, I. V. & Tyrrell, D. A. J. ( 2001;). Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82, 3011–3019.
    [Google Scholar]
  82. Kerr, J. R., McCoy, M., Burke, B., Mattey, D. L., Pravica, V. & Hutchinson, I. V. ( 2003;). Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol 56, 725–727.[CrossRef]
    [Google Scholar]
  83. Kinney, J. S., Anderson, L. J., Farrar, J., Strikas, R. A., Kumar, M. L., Kliegman, R. M., Sever, J. L., Hurwitz, E. S. & Sikes, R. K. ( 1988;). Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 157, 663–667.[CrossRef]
    [Google Scholar]
  84. Klouda, P. T., Corbin, S. A., Bradley, B. A., Cohen, B. J. & Woolf, A. D. ( 1986;). HLA and acute arthritis following human parvovirus infection. Tissue Antigens 28, 318–319.
    [Google Scholar]
  85. Knöll, A., Louwen, F., Kochanowski, B., Plentz, A., Stüssel, J., Beckenlehner, K., Jilg, W. & Modrow, S. ( 2002;). Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol 67, 259–266.[CrossRef]
    [Google Scholar]
  86. Koch, W. C. & Adler, S. P. ( 1989;). Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 8, 83–87.
    [Google Scholar]
  87. Koduri, P. R., Kumapley, R., Khokha, N. D. & Patel, A. R. ( 1997;). Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin. Ann Hematol 75, 67–68.[CrossRef]
    [Google Scholar]
  88. Koduri, P. R., Kumapley, R., Valladares, J. & Teter, C. ( 1999;). Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin – a report of eight patients. Am J Hematol 61, 16–20.[CrossRef]
    [Google Scholar]
  89. Komischke, K., Searle, K. & Enders, G. ( 1997;). Maternal serum alpha-fetoprotein and human chorionic gonadotropin in pregnant women with acute parvovirus B19 infection with and without fetal complications. Prenat Diagn 17, 1039–1046.[CrossRef]
    [Google Scholar]
  90. Kurpad, C., Mukherjee, P., Wang, X. S., Ponnazhagan, S., Li, L., Yoder, M. C. & Srivastava, A. ( 1999;). Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells. J Hematother Stem Cell Res 8, 585–592.[CrossRef]
    [Google Scholar]
  91. Kurtzman, G. J., Ozawa, K., Cohen, B. J., Hanson, G., Oseas, R. & Young, N. S. ( 1987;). Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 317, 287–294.[CrossRef]
    [Google Scholar]
  92. Kurtzman, G. J., Cohen, B., Meyers, P., Amunullah, A. & Young, N. S. ( 1988;). Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet ii, 1159–1162.
  93. Kurtzman, G. J., Cohen, B. J., Field, A. M., Oseas, R., Blaese, R. M. & Young, N. S. ( 1989a;). Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84, 1114–1123.[CrossRef]
    [Google Scholar]
  94. Kurtzman, G., Frickhofen, N., Kimball, J., Jenkins, D. W., Nienhuis, A. W. & Young, N. S. ( 1989b;). Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 321, 519–523.[CrossRef]
    [Google Scholar]
  95. Lee, P. R., Barnett, A. F., Scholer, J. F., Bryner, S. & Clark, W. H. ( 1960;). Rubella arthritis.A study of twenty cases. Calif Med 93, 125–128.
    [Google Scholar]
  96. Lehmann, H. W., Knöll, A., Küster, R.-M. & Modrow, S. ( 2003;). Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum 48, 1631–1638.[CrossRef]
    [Google Scholar]
  97. Levy, R., Weissman, A., Blomberg, G. & Hagay, Z. J. ( 1997;). Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 52, 254–259.[CrossRef]
    [Google Scholar]
  98. Li, X. & Rhode, S. L., III ( 1990;). Mutation of lysine 405 to serine in the parvovirus H-1 NS1 abolishes its functions for viral DNA replication, late promoter trans activation, and cytotoxicity. J Virol 64, 4654–4660.
    [Google Scholar]
  99. Lui, S. L., Luk, W. K., Cheung, C. Y., Chan, T. M., Lai, K. N. & Peiris, J. S. M. ( 2001;). Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 71, 59–64.[CrossRef]
    [Google Scholar]
  100. Luo, W. & Astell, C. R. ( 1993;). A novel protein encoded by small RNAs of parvovirus B19. Virology 195, 448–455.[CrossRef]
    [Google Scholar]
  101. Lyon, D. J., Chapman, C. S., Martin, C., Brown, K. E., Clewley, J. P., Flower, A. J. & Mitchell, V. E. ( 1989;). Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet i, 1085.
  102. Manaresi, E., Gallinella, G., Zerbini, M., Venturoli, S., Gentilomi, G. & Musiani, M. ( 1999;). IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J Med Virol 57, 174–178.[CrossRef]
    [Google Scholar]
  103. Manaresi, E., Zuffi, E., Gallinella, G., Gentilomi, G., Zerbini, M. & Musiani, M. ( 2001;). Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J Med Virol 64, 67–73.[CrossRef]
    [Google Scholar]
  104. Manaresi, E., Gallinella, G., Zuffi, E., Bonvicini, F., Zerbini, M. & Musiani, M. ( 2002;). Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol 67, 275–281.[CrossRef]
    [Google Scholar]
  105. McCarty, D. M., Ni, T.-H. & Muzyczka, N. ( 1992;). Analysis of mutations in adeno-associated virus Rep protein in vivo and in vitro. J Virol 66, 4050–4057.
    [Google Scholar]
  106. Miki, N. P. H. & Chantler, J. K. ( 1992;). Non-permissiveness of synovial membrane cells to human parvovirus in vitro. J Gen Virol 73, 1559–1562.[CrossRef]
    [Google Scholar]
  107. Miller, E., Fairley, C. K., Cohen, B. J. & Seng, C. ( 1998;). Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 105, 174–178.[CrossRef]
    [Google Scholar]
  108. Mimori, A., Misaki, Y., Hachiya, T., Ito, K. & Kano, S. ( 1994;). Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis. Rheumatol Int 14, 87–90.[CrossRef]
    [Google Scholar]
  109. Mitchell, L. A. ( 2002;). Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67, 267–274.[CrossRef]
    [Google Scholar]
  110. Mitchell, L. A., Leong, R. & Rosenke, K. A. ( 2001;). Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy? J Med Microbiol 50, 627–635.
    [Google Scholar]
  111. Moffatt, S., Tanaka, N., Tada, K., Nose, M., Nakamura, M., Muraoka, O., Hirano, T. & Sugamura, K. ( 1996;). A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70, 8485–8491.
    [Google Scholar]
  112. Momoeda, M., Kawase, M., Jane, S. M., Miyamura, K., Young, N. S. & Kajigaya, S. ( 1994a;). The transcriptional regulator YY1 binds to the 5′-terminal region of B19 parvovirus and regulates P6 promoter activity. J Virol 68, 7159–7168.
    [Google Scholar]
  113. Momoeda, M., Wong, S., Kawase, M., Young, N. S. & Kajigaya, S. ( 1994b;). A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol 68, 8443–8446.
    [Google Scholar]
  114. Morey, A. L., Ferguson, D. J. & Fleming, K. A. ( 1993;). Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol 169, 213–220.[CrossRef]
    [Google Scholar]
  115. Morita, E., Nakashima, A., Asao, H., Sato, H. & Sugamura, K. ( 2003;). Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G1 phase. J Virol 77, 2915–2921.[CrossRef]
    [Google Scholar]
  116. Mortimer, P. P., Humphries, R. K., Moore, J. G., Purcell, R. H. & Young, N. S. ( 1983;). A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 302, 426–429.[CrossRef]
    [Google Scholar]
  117. Moudgil, A., Shidban, H., Nast, C. C., Bagga, A., Aswad, S., Graham, S. L., Mendez, R. & Jordan, S. C. ( 1997;). Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64, 1847–1850.[CrossRef]
    [Google Scholar]
  118. Müller, J., Eis-Hübinger, A. M., Madlener, K., Küppers, C., Herzig, M. & Pötzsch, B. ( 2002;). Development and validation of a real-time PCR assay for routine testing of blood donations for parvovirus B19 DNA. Infus Ther Transfus Med 29, 254–258.
    [Google Scholar]
  119. Musiani, M., Zerbini, M., Gentilomi, G., Plazzi, M., Gallinella, G. & Venturoli, S. ( 1995;). Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 172, 1360–1363.[CrossRef]
    [Google Scholar]
  120. Nguyen, Q. T., Sifer, C., Schneider, V., Bernaudin, F., Auguste, V. & Garbarg-Chenon, A. ( 1998;). Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 352, 1524. 1524.
    [Google Scholar]
  121. Nguyen, Q. T., Sifer, C., Schneider, V., Allaume, X., Servant, A., Bernaudin, F., Auguste, V. & Garbarg-Chenon, A. ( 1999;). Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 37, 2483–2487.
    [Google Scholar]
  122. Nguyen, Q. T., Wong, S., Heegaard, E. D. & Brown, K. E. ( 2002;). Identification and characterization of a second novel human erythrovirus variant, A6. Virology 301, 374–380.[CrossRef]
    [Google Scholar]
  123. Nigro, G., Bastianon, V., Colloridi, V., Ventriglia, F., Gallo, P., D'Amati, G., Koch, W. C. & Adler, S. P. ( 2000;). Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 31, 65–69.[CrossRef]
    [Google Scholar]
  124. Nikkari, S., Roivainen, A., Hannonen, P., Mottonen, T., Luukkainen, R., Yli-Jama, T. & Toivanen, P. ( 1995;). Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 54, 597–600.[CrossRef]
    [Google Scholar]
  125. Nikkari, S., Lappalainen, H., Saario, R., Lammintausta, K. & Kotilainen, P. ( 1996;). Detection of parvovirus B19 in skin biopsy, serum, and bone marrow of a patient with fever, rash, and polyarthritis followed by pneumonia, pericardial effusion, and hepatitis. Eur J Clin Microbiol Infect Dis 15, 954–957.[CrossRef]
    [Google Scholar]
  126. Nocton, J. J., Miller, L. C., Tucker, L. B. & Schaller, J. G. ( 1993;). Human parvovirus B19-associated arthritis in children. J Pediatr 122, 186–190.[CrossRef]
    [Google Scholar]
  127. Nunoue, T., Kusuhara, K. & Hara, T. ( 2002;). Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J 21, 1133–1136.[CrossRef]
    [Google Scholar]
  128. O'Keeffe, S., O'Leary, D., Doyle, S., Kilty, C. & Kerr, S. ( 2003;). The detection of parvovirus B19 in human sera using antigen-capture EIA. Poster presented at the Meeting of the Society for General Microbiology (Irish Branch), National University of Ireland, Maynooth, Co. Kildare, Ireland, 24–25 April 2003.
  129. O'Neill, H. J. & Coyle, P. V. ( 1992;). Two anti-parvovirus B 19 IgM capture assays incorporating a mouse monoclonal antibody specific for B 19 viral capsid proteins VP 1 and VP 2. Arch Virol 123, 125–134.[CrossRef]
    [Google Scholar]
  130. Ozawa, K., Ayub, J., Hao, Y.S., Kurtzman, G., Shimada, T. & Young, N. ( 1987;). Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 61, 2395–2406.
    [Google Scholar]
  131. Ozawa, K., Ayub, J., Kajigaya, S., Shimada, T. & Young, N. ( 1988;). The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 62, 2884–2889.
    [Google Scholar]
  132. Palmer, P., Pallier, C., Leruez-Ville, M., Deplanche, M. & Morinet, F. ( 1996;). Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins. Clin Diagn Lab Immunol 3, 236–238.
    [Google Scholar]
  133. PHLS ( 1990;). Prospective study of human parvovirus (B19) infection in pregnancy.Public Health Laboratory Service Working Party on Fifth Disease. BMJ 300, 1166–1170.[CrossRef]
    [Google Scholar]
  134. Pillet, S., Le Guyader, N., Hofer, T., Nguyenkhac, F., Aubin, J. T., Gassmann, M., Fichelson, S. & Morinet, F. ( 2002;). Hypoxia upregulates the expression of human parvovirus B19. Paper presented at the IX Parvovirus Workshop, Bologna, Italy, 28–31 August 2002.
  135. Prowse, C., Ludlam, C. A. & Yap, P. L. ( 1997;). Human parvovirus B19 and blood products. Vox Sang 72, 1–10.[CrossRef]
    [Google Scholar]
  136. Pryde, P. G., Nugent, C. E., Pridjian, G., Barr, M., Jr & Faix, R. G. ( 1992;). Spontaneous resolution of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Obstet Gynecol 79, 859–861.
    [Google Scholar]
  137. Raab, U., Beckenlehner, K., Lowin, T., Niller, H.-H., Doyle, S. & Modrow, S. ( 2002;). NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293, 86–93.[CrossRef]
    [Google Scholar]
  138. Ray, N. B., Nieva, D. R., Seftor, E. A., Khalkhali-Ellis, Z. & Naides, S. J. ( 2001;). Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 44, 1582–1586.[CrossRef]
    [Google Scholar]
  139. Rayment, F. B., Crosdale, E., Morris, D. J., Pattison, J. R., Talbot, P. & Clare, J. J. ( 1990;). The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens. J Gen Virol 71, 2665–2672.[CrossRef]
    [Google Scholar]
  140. Reid, D. M., Reid, T. M. S., Brown, T., Rennie, J. A. N. & Eastmond, C. J. ( 1985;). Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet i, 422–425.
  141. Rodis, J. F., Hovick, T. J., Jr, Quinn, D. L., Rosengren, S. S. & Tattersall, P. ( 1988;). Human parvovirus infection in pregnancy. Obstet Gynecol 72, 733–738.
    [Google Scholar]
  142. Saldanha, J. & Minor, P. ( 1996;). Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 93, 714–719.[CrossRef]
    [Google Scholar]
  143. Saldanha, J., Lelie, N., Yu, M. W., Heath, A. & B19 Collaborative Study Group ( 2002;). Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 82, 24–31.[CrossRef]
    [Google Scholar]
  144. Sanghi, A., Morgan-Capner, P., Hesketh, L. & Elstein, M. ( 1997;). Zoonotic and viral infection in fetal loss after 12 weeks. Br J Obstet Gynaecol 104, 942–945.[CrossRef]
    [Google Scholar]
  145. Santagostino, E., Mannucci, P. M., Gringeri, A., Azzi, A. & Morfini, M. ( 1994;). Eliminating parvovirus B19 from blood products. Lancet 343, 798. 798.
    [Google Scholar]
  146. Santagostino, E., Mannucci, P. M., Gringeri, A., Azzi, A., Morfini, M., Musso, R., Santoro, R. & Schiavoni, M. ( 1997;). Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 37, 517–522.[CrossRef]
    [Google Scholar]
  147. Sato, H., Takakura, F., Kojima, E., Fukada, K., Okochi, K. & Maeda, Y. ( 1995;). Screening of blood donors for human parvovirus B19. Lancet 346, 1237–1238.
    [Google Scholar]
  148. Schleuning, M., Jager, G., Holler, E. & 7 other authors ( 1999;). Human parvovirus B19-associated disease in bone marrow transplantation. Infection 27, 114–117.[CrossRef]
    [Google Scholar]
  149. Schwarz, T. F., Roggendorf, M. & Deinhardt, F. ( 1988a;). Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods 20, 155–168.[CrossRef]
    [Google Scholar]
  150. Schwarz, T. F., Roggendorf, M., Hottentrager, B., Deinhardt, F., Enders, G., Gloning, K. P., Schramm, T. & Hansmann, M. ( 1988b;). Human parvovirus B19 infection in pregnancy. Lancet ii, 566–567.
  151. Schwarz, T. F., Roggendorf, M., Hottentrager, B., Modrow, S., Deinhardt, F. & Middeldorp, J. ( 1990;). Immunoglobulins in the prophylaxis of parvovirus B19 infection. J Infect Dis 162, 1214. 1214.[CrossRef]
    [Google Scholar]
  152. Searle, K., Guilliard, C. & Enders, G. ( 1997;). Parvovirus B19 diagnosis in pregnant women – quantification of IgG antibody levels (IU/ml) with reference to the international parvovirus B19 standard serum. Infection 25, 32–34.[CrossRef]
    [Google Scholar]
  153. Searle, K., Schalasta, G. & Enders, G. ( 1998;). Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. J Med Virol 56, 192–198.[CrossRef]
    [Google Scholar]
  154. Sebire, N. J. ( 2001;). Human parvovirus B19 and fetal death. Lancet 358, 1180. 1180.[CrossRef]
    [Google Scholar]
  155. Selbing, A., Josefsson, A., Dahle, L. O. & Lindgren, R. ( 1995;). Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 345, 660–661.
    [Google Scholar]
  156. Serjeant, G. R., Topley, J. M., Mason, K., Serjeant, B. E., Pattison, J. R., Jones, S. E. & Mohamed, R. ( 1981;). Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet ii, 595–597.
  157. Serjeant, G. R., Serjeant, B. E., Thomas, P. W., Anderson, M. J., Patou, G. & Pattison, J. R. ( 1993;). Human parvovirus infection in homozygous sickle cell disease. Lancet 341, 1237–1240.[CrossRef]
    [Google Scholar]
  158. Serjeant, B. E., Hambleton, I. R., Kerr, S., Kilty, C. G. & Serjeant, G. R. ( 2001;). Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 358, 1779–1780.[CrossRef]
    [Google Scholar]
  159. Servant, A., Laperche, S., Lallemand, F., Marinho, V., De Saint Maur, G., Meritet, J. F. & Garbarg-Chenon, A. ( 2002;). Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 76, 9124–9134.[CrossRef]
    [Google Scholar]
  160. Skjoldebrand-Sparre, L., Tolfvenstam, T., Papadogiannakis, N., Wahren, B., Broliden, K. & Nyman, M. ( 2000;). Parvovirus B19 infection: association with third-trimester intrauterine fetal death. Br J Obstet Gynaecol 107, 476–480.[CrossRef]
    [Google Scholar]
  161. Sloots, T. & Devine, P. L. ( 1996;). Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19. Eur J Clin Microbiol Infect Dis 15, 758–761.[CrossRef]
    [Google Scholar]
  162. Söderlund, M., Brown, C. S., Spaan, W. J., Hedman, L. & Hedman, K. ( 1995;). Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis 172, 1431–1436.[CrossRef]
    [Google Scholar]
  163. Söderlund, M., von Essen, R., Haapasaari, J., Kiistala, U., Kiviluoto, O. & Hedman, K. ( 1997;). Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 349, 1063–1065.[CrossRef]
    [Google Scholar]
  164. St Amand, J., Beard, C., Humphries, K. & Astell, C. R. ( 1991;). Analysis of splice junctions and in vitro and in vivo translation potential of the small, abundant B19 parvovirus RNAs. Virology 183, 133–142.[CrossRef]
    [Google Scholar]
  165. Thomas, I., Di Giambattista, M., Gérard, C., Mathys, E., Hougardy, V., Latour, B., Branckaert, T. & Laub, R. ( 2003;). Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang 84, 300–307.[CrossRef]
    [Google Scholar]
  166. Tolfvenstam, T., Rudén, U. & Broliden, K. ( 1996;). Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M. Clin Diagn Lab Immunol 3, 147–150.
    [Google Scholar]
  167. Tolfvenstam, T., Lundqvist, A., Levi, M., Wahren, B. & Broliden, K. ( 2000;). Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine 19, 758–763.[CrossRef]
    [Google Scholar]
  168. Tolfvenstam, T., Oxenius, A., Price, D. A. & 10 other authors ( 2001a;). Direct ex vivo measurement of CD8+ T-lymphocyte responses to human parvovirus B19. J Virol 75, 540–543.[CrossRef]
    [Google Scholar]
  169. Tolfvenstam, T., Papadogiannakis, N., Norbeck, O., Petersson, K. & Broliden, K. ( 2001b;). Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 357, 1494–1497.[CrossRef]
    [Google Scholar]
  170. Torok, T. J. ( 1990;). Human parvovirus B19 infections in pregnancy. Pediatr Infect Dis J 9, 772–776.
    [Google Scholar]
  171. Tuckerman, J. G., Brown, T. & Cohen, B. J. ( 1986;). Erythema infectiosum in a village primary school: clinical and virological studies. J R Coll Gen Pract 36, 267–270.
    [Google Scholar]
  172. Tyndall, A., Jelk, W. & Hirsch, H. H. ( 1994;). Parvovirus B19 and erosive polyarthritis. Lancet 343, 480–481.
    [Google Scholar]
  173. Valeur-Jensen, A. K., Pedersen, C. B., Westergaard, T., Jensen, I. P., Lebech, M., Andersen, P. K., Aaby, P., Pedersen, B. N. & Melbye, M. ( 1999;). Risk factors for parvovirus B19 infection in pregnancy. JAMA 281, 1099–1105.[CrossRef]
    [Google Scholar]
  174. Venturoli, S., Gallinella, G., Manaresi, E., Gentilomi, G., Musiani, M. & Zerbini, M. ( 1998;). IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen. J Infect Dis 178, 1826–1829.[CrossRef]
    [Google Scholar]
  175. von Landenberg, P., Lehmann, H. W., Knöll, A., Dorsch, S. & Modrow, S. ( 2003;). Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48, 1939–1947.[CrossRef]
    [Google Scholar]
  176. von Poblotzki, A., Gigler, A., Lang, B., Wolf, H. & Modrow, S. ( 1995a;). Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol 76, 519–527.[CrossRef]
    [Google Scholar]
  177. von Poblotzki, A., Hemauer, A., Gigler, A., Puchhammer-Stockl, E., Heinz, F. X., Pont, J., Laczika, K., Wolf, H. & Modrow, S. ( 1995b;). Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 172, 1356–1359.[CrossRef]
    [Google Scholar]
  178. von Poblotzki, A., Gerdes, C., Reischl, U., Wolf, H. & Modrow, S. ( 1996;). Lymphoproliferative responses after infection with human parvovirus B19. J Virol 70, 7327–7330.
    [Google Scholar]
  179. Vuorinen, T., Lammintausta, K., Kotilainen, P. & Nikkari, S. ( 2002;). Presence of parvovirus B19 DNA in chronic urticaric and healthy human skin. J Clin Virol 25, 217–221.[CrossRef]
    [Google Scholar]
  180. Wagner, A. D., Goronzy, J. J., Matteson, E. L. & Weyland, C. M. ( 1995;). Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 70, 261–265.[CrossRef]
    [Google Scholar]
  181. Wakamatsu, C., Takakura, F., Kojima, E. & 7 other authors ( 1999;). Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 76, 14–21.[CrossRef]
    [Google Scholar]
  182. Wattre, P., Dewilde, A., Subtil, D., Andreoletti, L. & Thirion, V. ( 1998;). A clinical and epidemiological study of human parvovirus B19 infection in fetal hydrops using PCR Southern blot hybridization and chemiluminescence detection. J Med Virol 54, 140–144.[CrossRef]
    [Google Scholar]
  183. Wegner, C. S. & Jordan, J. A. ( 2002;). Human parvovirus B19 binds placental cytotrophoblast cells via globoside receptor. Poster presented at the IX Parvovirus Workshop, Bologna, Italy, 28–31 August 2002.
  184. Weigel-Kelley, K. A., Yoder, M. C. & Srivastava, A. ( 2001;). Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 75, 4110–4116.[CrossRef]
    [Google Scholar]
  185. Weigel-Kelley, K. A., Yoder, M. C. & Srivastava, A. ( 2003;). α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry. Blood 102, 3927–3933.[CrossRef]
    [Google Scholar]
  186. White, D. G., Woolf, A. D., Mortimer, P. P., Cohen, B. J., Blake, D. R. & Bacon, P. A. ( 1985;). Human parvovirus arthropathy. Lancet i, 419–421.
  187. Williams, M. D., Cohen, B. J., Beddall, A. C., Pasi, K. J., Mortimer, P. P. & Hill, F. G. H. ( 1990;). Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 58, 177–181.[CrossRef]
    [Google Scholar]
  188. Woolf, A. D. & Cohen, B. J. ( 1995;). Parvovirus B19 and chronic arthritis – causal or casual association? Ann Rheum Dis 54, 535–536.[CrossRef]
    [Google Scholar]
  189. Woolf, A. D., Campion, G. V., Chishick, A., Wise, S., Cohen, B. J., Klouda, P. T., Caul, O. & Dieppe, P. A. ( 1989;). Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 149, 1153–1156.[CrossRef]
    [Google Scholar]
  190. Woolf, A. D., Hall, N. D., Goulding, N. J., Kantharia, B., Maymo, J., Evison, G. & Maddison, P. J. ( 1991;). Predictors of the long-term outcome of early synovitis: a 5-year follow-up study. Br J Rheumatol 30, 251–254.[CrossRef]
    [Google Scholar]
  191. Wright, C., Hinchliffe, S. A. & Taylor, C. ( 1996;). Fetal pathology in intrauterine death due to parvovirus B19 infection. Br J Obstet Gynaecol 103, 133–136.[CrossRef]
    [Google Scholar]
  192. Yaegashi, N. ( 2000;). Pathogenesis of nonimmune hydrops fetalis caused by intrauterine B19 infection. Tohoku J Exp Med 190, 65–82.[CrossRef]
    [Google Scholar]
  193. Yaegashi, N., Shiraishi, H., Tada, K., Yajima, A. & Sugamura, K. ( 1989;). Enzyme-linked immunosorbent assay for IgG and IgM antibodies against human parvovirus B19: use of monoclonal antibodies and viral antigen propagated in vitro. J Virol Methods 26, 171–181.[CrossRef]
    [Google Scholar]
  194. Yaegashi, N., Okamura, K., Yajima, A., Murai, C. & Sugamura, K. ( 1994;). The frequency of human parvovirus B19 infection in nonimmune hydrops fetalis. J Perinat Med 22, 159–163.[CrossRef]
    [Google Scholar]
  195. Yaegashi, N., Niinuma, T., Chisaka, H. & 7 other authors ( 1999;). Serologic study of human parvovirus B19 infection in pregnancy in Japan. J Infect 38, 30–35.[CrossRef]
    [Google Scholar]
  196. Yoto, Y., Kudoh, T., Haseyama, K., Suzuki, N., Oda, T., Katoh, T., Takahashi, T., Sekiguchi, S. & Chiba, S. ( 1995;). Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 91, 1017–1018.[CrossRef]
    [Google Scholar]
  197. Yoto, Y., Kudoh, T., Haseyama, K., Suzuki, N. & Chiba, S. ( 1996;). Human parvovirus B19 infection associated with acute hepatitis. Lancet 347, 868–869.[CrossRef]
    [Google Scholar]
  198. Young, N. S. ( 1996;). Parvoviruses. In Fields Virology, 3rd edn, pp. 2199–2220. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott-Raven.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05485-0
Loading
/content/journal/jmm/10.1099/jmm.0.05485-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error